Culligan Oncology (CGEM) unusual buy of 500 October $20 calls for $3.20, nice long consolidation flag forming and $750M low short float Biotech trading less than 2X Cash. CLN-619 data expected in Q2. Wedbush in February with a $30 target saying Cullinan Oncology has a diversified pipeline of six novel, clinical-stage therapies, with a focus on cancer. Distinctly, the company’s programs were developed or in-licensed without limitation to particular targets or platforms; rather, attractive targets were matched with optimal approaches on a case-by-case basis. Wedbush believes CLN-619 and zipalertinib have meaningful opportunity in gynecologic cancers and EGFR ex20ins NSCLC